United States

People: Colgate-Palmolive Co (CL.N)

CL.N on New York Stock Exchange

4:01pm EDT
Change (% chg)

$0.39 (+0.53%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Gayle, Helene 

Dr. Helene D. Gayle, M.D, is Independent Director of Colgate-Palmolive Company .She is also Director of The Coca-Cola Company from 2013.Dr. Gayle has served as Chief Executive Officer of the McKinsey Social Initiative since July 2015. Dr. Gayle previously served as President and Chief Executive Officer of CARE from 2006 to 2015. From 2001 to 2006, she was an executive in the Global Health program at the Bill & Melinda Gates Foundation. Dr. Gayle began her career in public health at the U.S. Centers for Disease Control in 1984 and held positions of increasing responsibility over her 20-year tenure there, ultimately becoming the director of the National Center for HIV, STD and TB Prevention and achieving the rank of Assistant Surgeon General and Rear Admiral in the United States Public Health Service. Dr. Gayle also serves on the boards of the Center for Strategic and International Studies, the Rockefeller Foundation, the New America Foundation and the White House Fellows Commission. She is a member of the Council on Foreign Relations, the Institute of Medicine and the American Public Health Association. Regulatory and Public Service—Extensive leadership experience in the global public health field through positions at CARE and the Bill & Melinda Gates Foundation and 20-year career at the U.S. Centers for Disease Control. She has experience managing international operations at CARE, one of the world’s leading humanitarian organizations with programs in nearly 70 countries around the world. She has in-depth knowledge of and expertise in the global public health field, a complementary industry. She has experience serving as a director of another U.S. public company.

Basic Compensation

Total Annual Compensation, USD 107,494
Restricted Stock Awards, USD 134,981
Long-Term Incentive Plans, USD --
All Other, USD 46,906
Fiscal Year Total, USD 289,381

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --